HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Albumin to Total Cholesterol Ratio and Mortality in Peritoneal Dialysis.

AbstractBackground:
Serum albumin and total cholesterol are associated with mortality. In clinical practice, evaluating the association of combining album and total cholesterol with mortality may be more reasonable. Thus, we examined the association between serum albumin to total cholesterol ratio and mortality in peritoneal dialysis (PD) patients.
Methods:
We conducted a retrospective cohort study of 3447 incident continuous ambulatory peritoneal dialysis (CAPD) patients from five PD centers in China from 1 January 2005 and 31 May 2020. The association between albumin to total cholesterol ratio and mortality was evaluated.
Results:
With a median follow-up of 39.3 months, 762 (22.1%) all-cause deaths occurred, including 382 (11.1%) cardiovascular deaths. As compared with a serum albumin to total cholesterol ratio of 0.77-0.82 (reference range), a higher ratio (>0.82) was associated with increased risks of all-cause mortality[hazards ratio (HR), 1.54; 95% confidence interval (CI), 1.16-2.05, E-value = 2.45] and cardiovascular mortality (HR, 2.10; 95% CI, 1.35-3.29, E-value = 3.62). A lower ratio (<0.77) was also associated with increased risks of all-cause mortality (HR, 1.46; 95% CI, 1.10-1.94, E-value = 2.28) and cardiovascular mortality (HR, 1.78; 95% CI, 1.14-2.78, E-value = 2.96) compared with the reference. No interaction was observed in subgroup analyses of age, sex, diabetes mellitus, hypertension, prior cardiovascular disease, and hyperlipidemia, and malnutrition (serum albumin <3.6 g/dL).
Conclusion:
An albumin to total cholesterol ratio before the start of PD between 0.77 and 0.82 was associated with a lower risk of death than a higher or lower ratio, resulting in a U-curve association. Therefore, serum albumin to total cholesterol ratio, as an inexpensive and readily available biochemical biomarker, may further improve the stratification risk of mortality in PD patients.
AuthorsXianfeng Wu, Jiao Meng, Lei Zhou, Xiaojiang Zhan, Yueqiang Wen, Xiaoyang Wang, Xiaoran Feng, Niansong Wang, Fenfen Peng, Junnan Wu
JournalFrontiers in medicine (Front Med (Lausanne)) Vol. 9 Pg. 896443 ( 2022) ISSN: 2296-858X [Print] Switzerland
PMID35755025 (Publication Type: Journal Article)
CopyrightCopyright © 2022 Wu, Meng, Zhou, Zhan, Wen, Wang, Feng, Wang, Peng and Wu.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: